SIETES :: 92005 citas

Resultados de la búsqueda por ALZHEIMER REFINAR BÚSQUEDA

1.

Donegan K, Fox N, Black N, Livingston G, Banerjee S, Burns A. Trends in diagnosis and treatment for people with dementia in the UK from 2005 to 2015: a longitudinal retrospective cohort study. The Lancet Public Health 2017;2:e149-56. [Ref.ID 101922]

2.

Obach M, Lopez P, Catalan A. Tratamiento farmacológico de la enfermedad de Alzheimer en la población de Catalu˜na. Med Clin (Barc) 2017;149:86-7. [Ref.ID 101905]

3.

Rochon PA, Vozoris N, Gill SS. The harms of benzodiazepines for patients with dementia . Can Med Assoc J 2017;189:E517-518. [Ref.ID 101525]

4.

Taipale H, Tolppanen A-M, Koponen M, Tanskanen A, Lavikainen P, Sund R, Tiihonen J, Hartikainen S. Risk of pneumonia associated with incident benzodiazepine use among community- dwelling adults with Alzheimer disease. Can Med Assoc J 2017;189:E519-529. [Ref.ID 101524]

5.

Patel AN, Lee S, Andrews HF, Pelton GH, Schultz SK, Sultzer DL, Mintzer J, de la Pena D, Gupta S, Colon S, Schimming C, Levin B, Devanand DP. Prediction of relapse after discontinuation of antipsychotic treatment in Alzheimer’s disease: the role of hallucinations. Am J Psychiatry 2016:1. [Ref.ID 100993]

6.

Anónimo. Solanezumab fails to reducre cognitive decline among patients with Alzheimer’s disease in clinical trial. DIA Daily 2016:1. [Ref.ID 100978]

7.

Anónimo. Alzheimer’s researchers optimistic after positive results from phase I clinical trial of aducanumab. DIA Daily 2016:3. [Ref.ID 100832]

8.

Nead KT, Gaskin G, Chester C, Swisher-McClure S, Leeper NJ, Shah NH. Association between androgen deprivation therapy and risk of dementia. JAMA Oncology 2016:13 de octubre. [Ref.ID 100814]

9.

Anónimo. Eli Lilly hopes third large-scale clinical trial will yield positive results for solanezumab as Alzheimer’s treatment. DIA Daily 2016:3. [Ref.ID 100809]

10.

Scheltens P, Blennow K, Breteler MMB, de Strooper B, Frisoni GB, Salloway S, Van der Flier WM. Alzheimer's disease. Lancet 2016;388:505-17. [Ref.ID 100647]

11.

Anónimo. FDA grants Biogen fast-track designation for Alzheimer’s drug. Kaiser Health News 2016:1. [Ref.ID 100625]

12.

Anónimo. Aducanumab shows encouraging results as Alzheimer’s treatment in early clinical trial. DIA Daily 2016:3. [Ref.ID 100617]

13.

Davis C, Lexchin J, Jefferson T, Gotzsche P, McKee M. "Adaptive pathways” to drug authorisation: adapting to industry?. BMJ 2016;354:i4437. [Ref.ID 100602]

14.

Reus VI, Fochtmann LJ, Eyler AE, Hilty DM, Horvitz-Lennon M, Jibson MD, Lopez OL, Mahoney J, Pasic J, Tan ZS, Wills CD, Rhoads R, Yager J. The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia. Am J Psychiatry 2016;173:543-6. [Ref.ID 100329]

15.

Kuller LH. Do proton pump inhibitors increase the risk of dementia?. JAMA Neurology 2016;73:379-81. [Ref.ID 100322]

16.

Risacher SL, McDonald BC, Tallman EF, West JD, Farlow MR, Unverzagt FW, Gao S, Boustani M, Crane PK, Petersen RC, Jack Jr CR, Jagust WJ, Aisen PS, Weiner MW, Saykin AJ, for the Alzheimer's Disease Neuroimaging Initiative. Association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal older adults. JAMA Neurology 2016;73:721-32. [Ref.ID 100315]

17.

Gomm W, von Holt K, Thomé F, Broich K, Maier W, Fink A, Doblhammer G, Haenisch B. Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. JAMA Neurology 2016;73:410-6. [Ref.ID 100299]

18.

Satizabal CL, Beiser AS, Chouraki V, Chêne G, Dufouil C, Seshadri S. Incidence of dementia over three decades in the Framingham Heart Study. N Engl J Med 2016;374:523-32. [Ref.ID 100130]

19.

Gray SL, Dublin S, Yu O, Walker R, Anderson M, Hubbard RA, Crane PK, Larson EB. Benzodiazepine use and risk of incident dementia or cognitive decline: prospective population based study. BMJ 2016;352:i90. [Ref.ID 100037]

20.

Anónimo. Donepezilo y riesgo de rabdomiólisis y de síndrome neuroléptico maligno. Butlletí de Farmacovigilància de Catalunya 2015;13:19. [Ref.ID 99837]